- $2.46bn
- $1.80bn
- $403.09m
- 72
- 26
- 53
- 49
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 94.9 | 132 | 201 | 289 | 403 |
Cost of Revenue | |||||
Gross Profit | 58.2 | 84 | 131 | 181 | 256 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 112 | 148 | 214 | 320 | 425 |
Operating Profit | -17.5 | -15.8 | -13.3 | -30.2 | -21.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.6 | -18.3 | -25.9 | -37.4 | -4.35 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.1 | -11.1 | -28.1 | -39.3 | -8.57 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.1 | -11.1 | -28.1 | -39.3 | -8.57 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.1 | -11.1 | -28.1 | -39.3 | -8.57 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.198 | -0.071 | -0.229 | -0.351 | -0.067 |
Dividends per Share |